Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + bevacizumab
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of irinotecan liposome and bevacizumab. Irinotecan liposome is a nanoliposomal formulation of the topoisomerase I inhibitor irinotecan, designed to enhance drug delivery and bioavailability while reducing toxicity compared to conventional irinotecan. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis in tumors. The combination aims to leverage the cytotoxic effects of DNA damage from irinotecan with the anti-angiogenic properties of bevacizumab for synergistic antitumor activity. This regimen has been investigated primarily in clinical trials for recurrent, platinum-resistant ovarian cancer, fallopian tube cancer, primary peritoneal cancer[2][4], and advanced pancreatic cancer after failure of first-line therapy[3]. Both agents are administered intravenously.
- Brand names
- OnivydeAvastin
- Other names
- irinotecan liposomal + bevacizumabirinotecan hydrochloride liposome injection + bevacizumab
02
Targets
TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on irinotecan liposome + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + bevacizumab.